ABSTRACT
PURPOSE: Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. METHODS: This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. RESULTS: From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69-0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06-2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p < 0.003). Higher plasma levels of CRP, PCT, and BNP were found in bacteremic than in non-bacteremic patients. The bacteremic group had consistently higher plasma levels of both pro- and anti-inflammatory cytokines. The blood neutrophil functional responses were similar in both groups of patients. CONCLUSIONS: Bacteremic pneumococcal CAP patients were significantly associated with higher in-hospital mortality, lower TCS, and longer LOS. HIV-infected patients showed a greater mortality which was not statistically significant. Bacteremic pneumococcal CAP patients had higher levels of biomarkers and systemic cytokines.
Subject(s)
Bacteremia/diagnosis , Bacteremia/pathology , Community-Acquired Infections/pathology , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/pathology , Streptococcus pneumoniae/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/mortality , C-Reactive Protein/analysis , Calcitonin/blood , Community-Acquired Infections/microbiology , Cytokines/blood , Female , Humans , Length of Stay , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Plasma/chemistry , Prospective Studies , Survival Analysis , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Community-acquired pneumonia (CAP) severity scores can identify patients at low risk for mortality who may be suitable for ambulatory care. Here, we follow the clinical course of hospitalized patients with CAP due to 2009 H1N1 influenza. OBJECTIVE: To evaluate the role of CAP severity scores as predictors of mortality. METHODS: This was a secondary data analysis of patients hospitalized with CAP due to 2009 H1N1 influenza confirmed by reverse transcriptase polymerase chain reaction enrolled in the CAPO (Community-Acquired Pneumonia Organization) international cohort study. CAP severity scores PSI (Pneumonia Severity Index), CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65 years) and CRB-65 (confusion, respiratory rate, blood pressure, age ≥ 65 years) were calculated. Actual and predicted mortality rates were compared. A total of 37 predictor variables were evaluated to define those associated with mortality. RESULTS: Data from 250 patients with CAP due to 2009 H1N1 influenza were analyzed. Patients with low predicted mortality rates (0-1.5%) had actual mortality rates ranging from 2.6% to 17.5%. Obesity and wheezing were the only novel variables associated with mortality. CONCLUSIONS: The decision to hospitalize a patient with CAP due to 2009 H1N1 influenza should not be based on current CAP severity scores, as they underestimate mortality rates in a significant number of patients. Patients with obesity or wheezing should be considered at an increased risk for mortality.
Subject(s)
Community-Acquired Infections/mortality , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/mortality , Pneumonia, Viral/mortality , Adult , Aged , Cohort Studies , Community-Acquired Infections/physiopathology , Community-Acquired Infections/virology , Female , Forecasting , Hospitalization , Humans , Influenza, Human/complications , Influenza, Human/physiopathology , Male , Middle Aged , Obesity/complications , Pneumonia, Viral/physiopathology , Pneumonia, Viral/virology , Respiratory Sounds/physiopathology , Risk Factors , Severity of Illness IndexABSTRACT
Twelve patients with active duodenal ulcer disease and Helicobacter pylori infection were treated with 1 g sucralfate q.d.s. for 1 month. Ulcers healed in 8 of the 12 patients without an alteration in the H. pylori-associated antral gastritis. Sucralfate produced a significant fall in basal acid output in all the patients, from a median of 4.8 (range 2.1-12.1) to 1.6 (0.4-8) mmol/h, P less than 0.01, whereas peak acid output was unchanged from 41 (21-59) before to 38 (24-55) mmol/h after treatment. Basal plasma gastrin concentrations and the meal-stimulated integrated gastrin response were not altered significantly by sucralfate: 8 (2-17) pmol/L and 732 (188-1045) pmol. min/L pre-treatment and 6 (2-17) pmol/L and 600 (140-1302) pmol. min/L post-treatment, respectively. The fall in basal acid output observed may contribute to prolonged duodenal ulcer remission after treatment with sucralfate.
Subject(s)
Duodenal Ulcer/drug therapy , Gastric Acid/metabolism , Gastrins/blood , Gastritis/drug therapy , Helicobacter Infections , Helicobacter pylori/drug effects , Sucralfate/pharmacology , Adult , Aged , Duodenal Ulcer/blood , Duodenal Ulcer/physiopathology , Female , Gastritis/blood , Gastritis/microbiology , Helicobacter Infections/blood , Helicobacter Infections/drug therapy , Helicobacter Infections/physiopathology , Humans , Male , Middle Aged , Pyloric Antrum/microbiologyABSTRACT
Patients with duodenal ulcers and Helicobacter pylori infection have elevated plasma gastrin concentrations which fall after suppression of the organism. This may be due to H. pylori elevating the pH of the antral mucous layer, therefore preventing luminal acid from inhibiting gastrin release. To test this idea, we measured the plasma gastrin concentrations under basal conditions and in response to 4% peptone when the gastric lumen was maintained at pH 2.5 and at pH 5.5 by gastric perfusion. We studied 11 duodenal ulcer patients before and after suppression of H. pylori. Gastrin concentrations were significantly higher before suppression of H. pylori than after treatment in all three states; basal gastrin (pmol/l) fell from 9.2 (3.7-23, median and range) to 5.1 (1.7-15) after treatment; from 11.3 (3.8-29) to 5.9 (5.7-6.1) at pH 2.5 and from 15.2 (3.9-32) to 7.15 (6.1-14) at pH 5.5. The ratio of peptone-stimulated gastrin at pH 2.5/pH 5.5 was similar before (0.8; 0.5-1.7) and after (0.8; 0.5-1.1) suppression of H. pylori. These results indicate that infection with H. pylori increases basal and peptone-stimulated plasma gastrin concentrations, and that this response is independent of luminal pH.
Subject(s)
Duodenal Ulcer/microbiology , Gastrins/metabolism , Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Amoxicillin/therapeutic use , Anti-Ulcer Agents/therapeutic use , Duodenal Ulcer/physiopathology , Female , Gastric Acid/metabolism , Helicobacter Infections/drug therapy , Humans , Hydrogen-Ion Concentration , Male , Metronidazole/therapeutic use , Middle Aged , Organometallic Compounds/therapeutic useABSTRACT
The effects of nifedipine and propranolol, alone and in combination, on collagen-induced platelet aggregation were studied in healthy volunteers using whole blood impedance aggregometry. No significant inhibition of platelet aggregation was found after the in vitro addition of propranolol, nifedipine or nifedipine vehicle or after nifedipine ex vivo. No interaction was found between in vitro propranolol and nifedipine, either in vitro or ex vivo.